Compare AbbVie Inc (ABBV) vs NetFlix Inc (NFLX) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

Netflix (NFLX) trades at $76.02, down 2.1% amid a bearish technical trend, though fundamentals remain strong with 2025 revenue of $45.18B and net income of $10.98B. The stock is near its 52-week low, with support at $75 and resistance at $77. Recent Q1 2026 earnings beat expectations with EPS of $1.23 versus $0.76 expected, highlighting robust operational performance despite market pessimism.

The outlook is mixed: strong fundamentals and a consensus price target of $114.75 suggest 51% upside, but technical weakness and competitive pressures pose risks. Investors should weigh the company's high ROE of 48.5% and scaling ad business against market sentiment and recent stock declines.